Chimerna Therapeutics

Executive Summary

Chimerna Therapeutics is a private RNA therapeutics company based in Cambridge, MA, founded in 2005. The company's core technology focuses on enabling RNA-based therapies by overcoming RNA instability, a key barrier to the clinical translation of RNA therapeutics. By leveraging proprietary chemical modifications and delivery platforms, Chimerna aims to develop stable and effective RNA medicines for a range of diseases. Though specific pipeline candidates are not publicly disclosed, the company's long history and focus on platform technology suggest a maturation of its research into preclinical or early clinical stages.

Upcoming Catalysts (preview)

• 2026Series B or C Financing Round70% success
• 2026IND Filing for Lead RNA Therapeutic Candidate50% success
• 2026Strategic Partnership with Major Pharma60% success